Daridorexant (Quviviq)
Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Daridorexant (Quviviq), 25 mg oral tablet, 50 mg oral tablet. Indication: Quviviq (daridorexant) is indicated for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Fields of Study & Subjects
Sleep and related disorders
Health Systems
Economic Evaluations
Quality of Life
Obstructive Sleep Apnea Research
Publication details
- Journal / source
- Canadian Journal of Health Technologies
- Volume
- 6
- Issue
- 3
- Publication date
- 2 March 2026
- Language
- EN